Trial Profile

An Observational, Follow-on Study to the MEDI4920 (D5100C00002) Study to Evaluate the Duration of Clinical and Pharmacodynamic Efficacy of 12 weeks of Treatment with VIB4920 in Subjects with Moderate to Severe Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Feb 2022 Status changed from recruiting to completed.
05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
02 Jun 2021 According to a Horizon Therapeutics plc media release, the company will present data (n=16) assessing the duration of clinical improvement beyond Day 169 of its original 2019 trial of people with moderate-to-severe rheumatoid arthritis (RA), during an oral session on 3rd Jun 2021 at the EULAR European Congress of Rheumatology (2021).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com